Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.

Yuki Owada-Ozaki,Satoshi Muto,Hironori Takagi,Takuya Inoue,Yuzuru Watanabe,Mitsuro Fukuhara,Takumi Yamaura,Naoyuki Okabe,Yuki Matsumura,Takeo Hasegawa,Jun Ohsugi,Mika Hoshino,Yutaka Shio,Hideaki Nanamiya,Jun-Ichi Imai,Takao Isogai,Shinya Watanabe,Hiroyuki Suzuki

Journal of Thoracic Oncology（2018）

引用 119|浏览31

暂无评分

摘要

High TMB in NSCLC is a poor prognostic factor. If high TMB is a predictor of the efficacy of immune checkpoint inhibitors, postoperative adjuvant therapy with immune checkpoint inhibitors may contribute to improvement of recurrence and OS.

查看译文

关键词

Tumor mutation burden,NSCLC,Prognosis,Immune-checkpoint inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要